Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ross J. Baldessarini, D.Sc., M.D.

Co-Author

This page shows the publications co-authored by Ross Baldessarini and Bruce Cohen.
Connection Strength

1.107
  1. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 1993 Sep; 9(2):117-24.
    View in: PubMed
    Score: 0.151
  2. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry Suppl. 1992 May; (17):12-6.
    View in: PubMed
    Score: 0.138
  3. Cohen BM, Benes FM, Baldessarini RJ. Atypical neuroleptics, dose-response relationships, and treatment-resistant psychosis. Arch Gen Psychiatry. 1989 Apr; 46(4):381-3.
    View in: PubMed
    Score: 0.112
  4. Cohen BM, Babb S, Campbell A, Baldessarini RJ. Persistence of haloperidol in the brain. Arch Gen Psychiatry. 1988 Sep; 45(9):879-80.
    View in: PubMed
    Score: 0.107
  5. Baldessarini RJ, Cohen BM. Regulation of psychiatric practice. Am J Psychiatry. 1986 Jun; 143(6):750-1.
    View in: PubMed
    Score: 0.092
  6. Cohen BM, Baldessarini RJ. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry. 1985 Apr; 142(4):489-90.
    View in: PubMed
    Score: 0.085
  7. Cohen BM, Baldessarini RJ. Haloperidol levels and clinical response. Am J Psychiatry. 1981 Nov; 138(11):1513-4.
    View in: PubMed
    Score: 0.067
  8. Tohen M, Strakowski SM, Zarate C, Hennen J, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000 Sep 15; 48(6):467-76.
    View in: PubMed
    Score: 0.062
  9. Cohen BM, Herschel M, Miller E, Mayberg H, Baldessarini RJ. Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology. 1980 Jul; 19(7):663-8.
    View in: PubMed
    Score: 0.061
  10. Tohen M, Hennen J, Zarate CM, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000 Feb; 157(2):220-8.
    View in: PubMed
    Score: 0.059
  11. Baldessarini RJ, Cohen BM, Teicher MH. Clinical dosing of neuroleptics. Psychopharmacol Ser. 1993; 10:138-48.
    View in: PubMed
    Score: 0.036
  12. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl). 1992; 108(3):338-44.
    View in: PubMed
    Score: 0.034
  13. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988 Jan; 45(1):79-91.
    View in: PubMed
    Score: 0.026
  14. Arana GW, Lamont JS, Baldessarini RJ, Teicher MH, Neumeyer JL, Cohen BM. Binding of [3H]apomorphine to an aporphine binding site as well as to dopamine sites in tissue from bovine caudate nucleus. Neuropharmacology. 1984 Aug; 23(8):885-92.
    View in: PubMed
    Score: 0.020
  15. Campbell A, Herschel M, Sommer B, Madsen JR, Cohen BM, Baldessarini RJ. Circadian changes in the destruction and effects of haloperidol in the rat. Neuropharmacology. 1982 Jul; 21(7):663-9.
    View in: PubMed
    Score: 0.017
  16. Campbell A, Herschel M, Cohen BM, Baldessarini RJ. Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. Life Sci. 1980 Aug 25; 27(8):633-40.
    View in: PubMed
    Score: 0.015
  17. Keck PE, Cohen BM, Baldessarini RJ, McElroy SL. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry. 1989 Oct; 146(10):1289-92.
    View in: PubMed
    Score: 0.007
  18. Teicher MH, Cohen BM, Baldessarini RJ, Cole JO. Severe daytime somnolence in patients treated with an MAOI. Am J Psychiatry. 1988 Dec; 145(12):1552-6.
    View in: PubMed
    Score: 0.007
  19. Svendsen CN, Froimowitz M, Hrbek C, Campbell A, Kula N, Baldessarini RJ, Cohen BM, Babb S, Teicher MH, Bird ED. Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at D1 and D2 receptors in rat brain. Neuropharmacology. 1988 Nov; 27(11):1117-24.
    View in: PubMed
    Score: 0.007
  20. Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP. Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. J Chromatogr. 1984 May 11; 307(2):457-63.
    View in: PubMed
    Score: 0.005
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.